A group of researchers has found a new way to limit excessive immune responses, which may point in a new direction for research in and treatment of e.g. autoimmune diseases.
Researchers from Aarhus University Hospital and Aarhus University in Denmark in collaboration with researchers from Colorado in the United States have found a new way to treat the inflammation involved in chronic diseases such as psoriasis, asthma and HIV. A group of transmitter substances (cytokines) in the immune system, the so-called IL-1 family, has been shown to play an important role in many of these diseases by regulating the body’s immune responses.
Professor Charles A. Dinarello from University of Colorado Denver is also an honorary doctor at Aarhus University. He is an expert in regulation and transmission of these cytokines. He is primarily known for discovering the important cytokine IL-1(-?), which plays an important role in countless diseases. In collaboration with Charles Dinarello, the Danish researchers have investigated a more efficient way of reducing the effect of the IL-1 family and in this way improve treatment of chronic inflammatory diseases.
Previous research has often focused on blocking a single cytokine or signaling pathway at a time. However, many diseases and sequela are driven by more than one cytokine. This has caused researchers to wonder if it could be possible to block more important signaling pathways of the IL-1 family at the same time, and in this way make it possible to develop better treatments. The researchers try to find a broader anti-inflammatory treatment impacting several important cytokines at the same time, but also trying to avoid that this causes unintended side-effects.
In this study, the researchers have investigated if a receptor (IL-1R3), which is not just involved in the signaling of one but six different inflammatory cytokines in the IL-1 family, could be a possible target in the treatment of chronic inflammatory disease. Using an antibody to block the effect of IL-1R3, it was possible for the researchers to investigate the effects in both studies on cells and mice.
In this way, researchers could study some of the consequences of the blocking of this receptor on the immune system. At the same time, the researchers specifically studied the effect of blocking IL-1R3 in mice with either gout, acute allergic inflammation (asthma) or psoriasis.
– The experiments showed that it was possible to effectively block the receptor and reduce manifestation of diseases, which underlines the potentials in our new approach, says MD and PhD Jesper Falkesgaard Højen.
– Even though new questions arise as a consequences of these results, we have managed to describe a new and effective approach to block IL-1 family driven inflammation, and in this way we have possibly contributed with a new direction to study and treat chronic inflammatory conditions driven by the IL-1 family.
The Latest on: Autoimmune diseases
via Google News
The Latest on: Autoimmune diseases
- Amgen supports advancement of AMG 634 for global health diseases in developing countrieson June 24, 2020 at 1:11 am
"AMG 634 could have potential for patients suffering from ENL and TB, two diseases that continue to challenge many ... and a significant number of leprosy patients suffer from ENL, an autoimmune ...
- Berlin Cures Holding AG: Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19on June 23, 2020 at 11:05 pm
Berlin Cures to Evaluate BC 007, an Aptamer, in Patients for the Treatment of COVID-19 Phase II/III clinical trial is scheduled to start in the second half of 2020 Berlin, Germany - 24 June 2020 ...
- Yes, I Have an Autoimmune Disease. But That’s Just One Part of Who I Amon June 23, 2020 at 2:11 pm
But then when I was 27, my doctor found a cyst the size of a golf ball in my right lung. I had major surgery to remove it, and then had to go through intense recovery. I took medical leave from my job ...
- Autoimmune Disease Diagnostics Market Will Reach US Dollor 16 Bn Globally, in 2027on June 23, 2020 at 5:52 am
The global Autoimmune Disease Diagnostics Market size is expected to reach USD 5 billion by 2027, at a significant growth rate of 7 % during the forecasted period 2020 to 2027. The market report ...
- Autoimmune Disease Diagnosis Market Revenue Expected to Reach $3.5 Billion by 2030:Market Industry Reportson June 23, 2020 at 5:46 am
Autoimmune disease occurs when the human body’s defense system fails to differentiate between naturally present cells and the foreign cells. This condition then allows the body ...
- Oppilan Pharma Announces Positive Phase 1 Data for its Ulcerative Colitis Drug OPL-002 at Digestive Disease Week 2020 Virtual Scientific Programon June 23, 2020 at 5:30 am
Potential best-in-class profile for an oral sphingosine-1-phosphate receptor modulator - Dose-dependent reduction in circulating lymphocytes - - Rapid lymphocyte recovery ...
- Former Sacramento Firefighter Gets Second Chance At Life After Battling Cancer, Autoimmune Disorder, Kidney Diseaseon June 21, 2020 at 10:49 pm
It's been a long journey for 45-year-old former firefighter Scott Schneider. At age three he knew he wanted to be a firefighter, but he was diagnosed with kidney disease as a child.
- Autoimmune Disease: How to Turn White Blood Cells From Attacking the Body to Protecting Iton June 17, 2020 at 10:26 am
Autoimmune diseases are currently treated using immunosuppressive drugs, which suppress the whole immune system.
- Global Autoimmune Diseases Treatment Market 2020 Industry Emerging Trend, Market Players, Revenue Insights to 2026on June 17, 2020 at 3:57 am
The report provides rational insights along with historical and forecast data to aid in better understanding of ...
- Autoimmune diseases: we discovered how to turn white blood cells from attacking the body to protecting iton June 15, 2020 at 6:48 am
But for people with autoimmune conditions, the body’s white blood cells instead perceive other cells and tissues in the body to be a threat and attacks them. While some immune disorders, like ...
via Bing News